Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-α: A description of a phase I-II protocol

References

• Wondergem J, Bulger RE, Strebel FR, Newman RA, Travis EL, Stephens LC, Bull JM. Effect of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury. Cancer Res 1988; 48: 440–446
   PubMed Web of Science ®Google Scholar
• Ohno S, Siddik ZH, Baba H, Stephens LC, Strebel FR, Wondergem J, Khokhar AR, Bull JM. Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res 1991; 51: 2994–3000
   PubMed Web of Science ®Google Scholar
• Baba H, Siddik ZH, Strebel FR, Jenkins GN, Bull JM. Increased therapeutic gain of combined cis-diamminedichloroplatinum(II) and whole body hyperthermia therapy by optimal heat/drug scheduling. Cancer Res 1989; 49: 7041–7044
   PubMed Web of Science ®Google Scholar
• Bull J, Loo C, Strebel F, Jenkins G, Tomoda M, Rowe R. Treatment of a highly metastatic mammary adenocarcinoma with fever-range, long-duration, low temperature (40°C for 6 h) whole body hyperthermia (LL-WBH) combined with gemcitabine (dFdC) in rats. Proceedings of the 90th meeting of the American Association for Cancer Research, C Croce, Philadelphia, PA 1999; 3643
   Google Scholar
• Bull J, Strebel F, Jenkins G, Tomoda M, Rowe R. Sequence-dependency of antitumor effect of gemcitabine combined with cisplatin in the highly metastatic MTLN3 rat mammary adenocarcinoma. Proceedings of the 91^st Annual Meeting of the American Association for Cancer Research, FJ Rauscher, San Francisco, CA 2000; 410
   Google Scholar
• Bull J, Strebel F, Rowe R, Deng W. The importance of schedule in whole-body thermochemotherapy. Int J Hyperthermia 2008; 2: 171–181
   Google Scholar
• Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 2006; 107: 2254–2261
   PubMed Web of Science ®Google Scholar
• Fidler I. Regulation of neoplastic angiogenesis. J Natl Cancer Inst Monogr 2001; 28: 10–14
   PubMedGoogle Scholar
• Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992; 3: 89–96
   PubMedGoogle Scholar
• Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 119–134
   PubMed Web of Science ®Google Scholar
• Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 2002; 71: 565–581
   PubMed Web of Science ®Google Scholar
• Marler JJ, Rubin JB, Trede NS, Connors S, Grier H, Upton J, Mulliken JB, Folkman J. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: Report of 2 cases. Pediatrics 2002; 109: E37
   PubMed Web of Science ®Google Scholar
• Matsuda H, Strebel FR, Kaneko T, Danhauser LL, Jenkins GN, Toyota N, Bull JM. Long duration-mild whole body hyperthermia of up to 12 hours in rats: Feasibility, and efficacy on primary tumour and axillary lymph node metastases of a mammary adenocarcinoma: Implications for adjuvant therapy. Int J Hyperthermia 1997; 13: 89–98
   PubMed Web of Science ®Google Scholar
• Bull JMC, Strebel F, Jenkins G, Nagle V. A preclinical breast cancer protocol combining fever-range whole-body hyperthermia with Doxil. Proceedings of the 16th Annual San Antonio Conference on Breast Cancer, K Osborne, San Antonio, TX 1998; 32
   Google Scholar
• Pritchard MT, Ostberg JR, Evans SS, Burd R, Kraybill W, Bull JM, Repasky EA. Protocols for simulating the thermal component of fever: Preclinical and clinical experience. Methods 2004; 32: 54–62
   PubMed Web of Science ®Google Scholar
• Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncol 1984; 2: 187–193
   PubMed Web of Science ®Google Scholar
• Tuma RS. Sometimes size doesn't matter: Reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst 2006; 98: 1272–1274
   PubMedGoogle Scholar
• Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 2006; 42: 1031–1039
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis research: From laboratory to clinic. Forum (Genoa, Italy) 1999; 9: 59–62
   PubMedGoogle Scholar
• Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995; 14: 1149–1161
   PubMed Web of Science ®Google Scholar
• Ahn C. An evaluation of phase I cancer clinical trial designs. Stat Med 1998; 17: 1537–1549
   PubMed Web of Science ®Google Scholar
• Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PW, Lee JE, Janjan NA, Charnsangavej C, Abbruzzese JL. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 2001; 7: 2246–2253
   PubMed Web of Science ®Google Scholar
• Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21: 3402–3408
   PubMed Web of Science ®Google Scholar
• Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997; 24: S7–2-7
   PubMedGoogle Scholar
• Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2′,2′-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer chemotherapy and pharmacology 1991; 27: 258–262
   PubMed Web of Science ®Google Scholar
• Kraybill WG, Olenki T, Evans SS, Ostberg JR, O'Leary KA, Gibbs JF, Repasky EA. A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: Correlation with mouse models. Int J Hyperthermia 2002; 18: 253–266
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176–181
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Amer Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Song CW, Park H, Griffin RJ. Improvement of tumor oxygenation by mild hyperthermia. Radiation research 2001; 155: 515–528
   PubMed Web of Science ®Google Scholar
• Song CW, Park HJ, Lee CK, Griffin R. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 2005; 21: 761–767
   PubMed Web of Science ®Google Scholar
• Jain RK. Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies. J Natl Cancer Inst 1989; 81: 570–576
   PubMed Web of Science ®Google Scholar
• Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 1991; 51: 6691–6694
   PubMed Web of Science ®Google Scholar
• Jain RK. The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation 1997; 4: 1–23
   PubMedGoogle Scholar
• Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25: 2607–2615
   PubMed Web of Science ®Google Scholar
• Haddock MG, Swaminathan R, Foster NR, Hauge MD, Martenson JA, Camoriano JK, Stella PJ, Tenglin RC, Schaefer PL, Jr Moore DF, et al. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: Results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 2007; 25: 2567–2572
   PubMedGoogle Scholar
• Ostberg JR, Repasky EA. Use of mild, whole body hyperthermia in cancer therapy. Immunol Invest 2000; 29: 139–142
   PubMedGoogle Scholar
• Burd R, Dziedzic TS, Xu Y, Caligiuri MA, Subjeck JR, Repasky EA. Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. J Cell Physiol 1998; 177: 137–147
   PubMed Web of Science ®Google Scholar
• Chen Q, Fisher DT, Clancy KA, Gauguet JM, Wang WC, Unger E, Rose-John S, von Andrian UH, Baumann H, Evans SS. Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nature immunology 2006; 7: 1299–1308
   PubMed Web of Science ®Google Scholar
• Ostberg JR, Repasky EA. Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function. Cancer Immunol Immunother 2006; 55: 292–298
   PubMed Web of Science ®Google Scholar
• Niessner A, Sato K, Chaikof EL, Colmegna I, Goronzy JJ, Weyand CM. Pathogen-sensing plasmacytoid \dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 2006; 114: 2482–2489
   PubMed Web of Science ®Google Scholar
• Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, Popescu F, Xiao Z. Signals required for programming effector and memory development by CD8 + T cells. Immunological reviews 2006; 211: 81–92
   PubMed Web of Science ®Google Scholar
• Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5: 2726–2734
   PubMed Web of Science ®Google Scholar
• Pillarisetty VG, Miller G, Shah AB, DeMatteo RP. GM-CSF expands dendritic cells and their progenitors in mouse liver. Hepatology (Baltimore, Md) 2003; 37: 641–652
   PubMedGoogle Scholar
• Pulendran B, Dillon S, Joseph C, Curiel T, Banchereau J, Mohamadzadeh M. Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8 + Tc1 responses in vivo. Eur J Immun 2004; 34: 66–73
   PubMed Web of Science ®Google Scholar
• Gomez-Cambronero J. Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS letters 2003; 550: 94–100
   PubMed Web of Science ®Google Scholar
• Shen L, Smith JM, Shen Z, Hussey SB, Wira CR, Fanger MW. Differential regulation of neutrophil chemotaxis to IL-8 and fMLP by GM-CSF: Lack of direct effect of oestradiol. Immunology 2006; 117: 205–212
   PubMedGoogle Scholar
• Davidson SE, Trotti A, Ataman OU, Seong J, Lau FN, da Motta NW, Jeremic B. Improving the capture of adverse event data in clinical trials: The role of the international atomic energy agency. Int J Radiat Oncol Biol Phys 2007; 69: 1218–1213
   PubMed Web of Science ®Google Scholar